Abstract
Hyperprolactinemia is the most common abnormality of the hypothalamic–pituitary axis. The aim of this study was to investigate the clinical and radiological features of patients with macroprolactinemia. The study population consisted of patients with elevated serum prolactin (PRL) concentrations who presented to our Endocrinology outpatient clinic. Detection of macroprolactin (macroPRL) was performed using the polyethylene glycol precipitation method. Patients in which macroPRL made up more than 60% of total PRL levels were stratified into the macroPRL group, while the remaining patients were placed in the monomeric prolactin (monoPRL) group. A total of 337 patients were enrolled with a mean age of 33.8 ± 10.8 (16–66) years and a male/female ratio of 29/308. Eighty-eight of the patients (26.1%) had an elevated macroPRL level. The mean age in the monoPRL group was higher than in the macroPRL group (35.0 ± 10.1 vs. 30.7 ± 9.8, P = 0.016). The mean PRL levels (ng/ml) in the macroPRL and monoPRL groups were similar (168.0 ± 347.0 vs. 238.8 ± 584.9, P = 0.239). Frequency of amenorrhea, infertility, irregular menses, gynecomastia, and erectile dysfunction were also similar in both groups. More patients in the macroPRL group were asymptomatic compared to the monoPRL group (30.2 vs. 12.0%, P = 0.006). Compared to the macroPRL group, the monoPRL group had a higher frequency of galactorrhea (39.2 vs. 57.1%, P = 0.04) and abnormal magnetic resonance imaging findings (65.3 vs. 81.1%, P = 0.02). Elevated macroPRL levels should be considered a pathological biochemical variant of hyperprolactinemia that may present with any of the conventional symptoms and radiological findings generally associated with elevated PRL levels.
Similar content being viewed by others
References
D.C Aron, J.W Findling, J.B Tyrrell, Hypothalamus and pituitary gland, in Basic and Clinical Endocrinology, 7th edn. by F.S. Greenspan, D.G Gardner (Lange Medical Books-McGraw Hill, New York 2004), pp. 106–175
O.M. Hauache, A.J. Rocha, A.C. Maia Jr., R.M. Maciel, J.G. Vieira, Screening for macroprolactinaemia and pituitary imaging studies. Clin. Endocrinol. (Oxf) 57, 327–331 (2002)
H. Leslie, C.H. Courtney, P.M. Bell et al., Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method. J. Clin. Endocrinol. Metab. 86, 2743–2746 (2001)
J.G. Vieira, T.T. Tachibana, L.H. Obara, R.M. Maciel, Extensive experience and validation of polyethylene glycol precipitation as a screening method for macroprolactinemia. Clin. Chem. 44, 1758–1759 (1998)
M.R. Sánchez-Eixerés, M. Mauri, R. Alfayate et al., Prevalence of macroprolactin detected by Elecsys 2010. Horm. Res. 56, 87–92 (2001)
T.P. Smith, A.M. Suliman, M.N. Fahie-Wilson, T.J. McKenna, Gross variability in the detection of prolactin in sera containing big big prolactin (macroprolactin) by commercial immunoassays. J. Clin. Endocrinol. Metab. 87, 5410–5415 (2002)
S. Vallette-Kasic, I. Morange-Ramos, A. Selim et al., Macroprolactinemia revisited: A study on 106 patients. J. Clin. Endocrinol. Metab. 87, 581–588 (2002)
B. Cavaco, V. Leite, M.A. Santos, E. Arranhado, L.G. Sobrinho, Some forms of big big prolactin behave as a complex of monomeric prolactin with an immunoglobulin G in patients with macroprolactinemia or prolactinoma. J. Clin. Endocrinol. Metab. 80, 2342–2346 (1995)
V. Leite, H. Cosby, L.G. Sobrinho, M.A. Fresnoza, M.A. Santos, H.G. Friesen, Characterization of big, big prolactin in patients with hyperprolactinemia. Clin. Endocrinol. (Oxf) 37, 365–372 (1992)
T. Mancini, F.F. Casanueva, A. Giustina, Hyperprolactinemia and prolactinomas. Endocrinol. Metab. Clin. N. Am. 37(1), 67–99 (2008)
A.O. Olukoga, J.W. Kane, Macroprolactinaemia: Validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition. Clin. Endocrinol. (Oxf) 51, 119–126 (1999)
A.M. Suliman, T.P. Smith, J. Gibney, T.J. McKenna, Frequent misdiagnosis and mismanagement of hyperprolactinemic patients before the introduction of macroprolactin screening: Application of a new strict laboratory definition of macroprolactinemia. Clin. Chem. 49, 1504–1509 (2003)
K. Ichihara, K. Miyai, Detection of asymptomatic prolactinoma by a mass screening program. Rinsho Byori 38, 667–674 (1990)
T. Bjøro, L. Mørkrid, R. Wergeland et al., Frequency of hyperprolactinaemia due to large molecular weight prolactin (150–170 kD PRL) Scand. J. Clin. Lab. Invest. 55, 139–147 (1995)
M.N. Fahie-Wilson, S.G. Soule, Macroprolactinaemia: Contribution to hyperprolactinaemia in a district general hospital and evaluation of a screening test based on precipitation with polyethylene glycol. Ann. Clin. Biochem. 34, 252–258 (1997)
Y.N. Sinha, Structural variants of prolactin: Occurrence and physiological significance. Endocr. Rev. 16, 354–369 (1995)
C.R. Smith, M.R. Norman, Prolactin and growth hormone: molecular heterogeneity and measurement in serum. Ann. Clin. Biochem. 27, 542–550 (1990)
S. Melmed, F.F. Casanueva, A.R. Hoffman, D.L. Kleinberg, V.M. Montori, J.A. Schlechte, J.A. Wass, Endocrine Society Diagnosis and treatment of hyperprolactinemia: An Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 273–288 (2011)
J. Gibney, T.P. Smith, T.J. McKenna, The impact on clinical practice of routine screening for macroprolactin. J. Clin. Endocrinol. Metab. 90, 3927–3932 (2005)
F.F. Casanueva, M.E. Molitch, J.A. Schlechte et al., Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin. Endocrinol. (Oxf) 65(2), 265–273 (2006)
I.R. Wallace, N. Satti, C.H. Courtney, H. Leslie, P.M. Bell, S.J. Hunter, D.R. McCance, B. Sheridan, A.B. Atkinson, Ten-year clinical follow-up of a cohort of 51 patients with macroprolactinemia establishes it as a benign variant. J. Clin. Endocrinol. Metab. 95(7), 3268–3271 (2010)
T. Rand, E. Kink, M. Sator et al., MRI of microadenomas in patients with hyperprolactinemia. Neuroradiology 38, 744–746 (1996)
A. Bayrak, P. Saadat, E. Mor, L. Chong, R.J. Paulson, R.Z. Sokol, Pituitary imaging is indicated for the evaluation of hyperprolactinemia. Fertil. Steril. 84, 181–185 (2005)
G. Tamer, A. Telci, M. Mert, et al., Prevalence of pituitary adenomas in macroprolactinemic patients may be higher than it is presumed. Endocrine. (2011)
P.E. Garnier, M.L. Aubert, S.L. Kaplan, M.M. Grumbach, Heterogeneity of pituitary and plasma prolactin in man: decreased affinity of “big” prolactin in a radioreceptor assay and evidence for its secretion. J. Clin. Endocrinol. Metab. 47, 1273–1281 (1978)
A.D. Rogol, R.C. Eastman, T. Manolio, S.W. Rosen, Unusual heterogeneity of circulating prolactin in an acromegalic. J. Endocrinol. Invest. 4, 221–227 (1981)
F. Larrea, C. Villanueva, M. Carmen Cravioto, A. Escorza, O. del Real, Further evidence that big–big prolactin is preferentially secreted in women with hyperprolactinemia and normal ovarian function. Fertil. Steril. 44, 25–30 (1985)
N. Hattori, K. Ikekubo, T. Ishihara, K. Moridera, M. Hino, H. Kurahachi, Correlation of the antibody titers with serum prolactin levels and their clinical course in patients with anti-prolactin autoantibody. Eur. J. Endocrinol. 130, 438–445 (1994)
D.L. Kleinberg, G.L. Noel, A.G. Frantz, Galactorrhea: A study of 235 cases including 48 with pituitary tumors. N. Engl. J. Med. 296, 589–600 (1977)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Isik, S., Berker, D., Tutuncu, Y.A. et al. Clinical and radiological findings in macroprolactinemia. Endocrine 41, 327–333 (2012). https://doi.org/10.1007/s12020-011-9576-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-011-9576-9